Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease

Serum leucine-rich alpha-2 glycoprotein (LRG) can monitor disease activities during biologics treatment in patients with inflammatory bowel disease (IBD). It is unclear whether the pretreatment serum LRG level can predict clinical effectiveness including serum trough levels of ustekinumab in patients with IBD. This multicenter prospective cohort study included 184 patients (Crohn's disease, 104; ulcerative colitis, 80) who received ustekinumab (n = 119) or anti-tumor necrosis factor (n = 65) between January 2019 and March 2023. Multivariate logistic regression analysis revealed serum LRG level at week 0 (0w-LRG, odds ratio 0.12, 95% confidence interval 0.02-0.68) as one of significant factors for clinical remission at week 8. We divided patients into the low- and the high-LRG groups by the median 0w-LRG (18.2 µg/mL) and compared the effectiveness. In patients who received ustekinumab, the proportion of clinical remission at week 8 was significantly different between in the low- (76.9%) and in the high-LRG group (59.3%, P = 0.038), and median serum trough level at week 8 was significantly different between in the low- (10.9 µg/mL, interquartile range 6.7-13.4) and the high-LRG group (5.3 µg/mL, interquartile range 2.4-8.3, P < 0.001). The 0w-LRG can predict the effectiveness including serum trough levels of ustekinumab during induction treatment for patients with IBD.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2024-11-29
DOI
https://doi.org/10.1038/s41598-024-80285-6
Citations
5
Primary Topic
Clusterin in disease pathology
Type
article
Field-Weighted Citation Impact
1.41

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease

Tomomi Yamada, Yoshiki Tsujii, Taku Tashiro, Ichizo Kobayashi et al.
5 citations
Scientific Reports
Clusterin in disease pathology
1.41
article

Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease

Tomomi Yamada, Yoshiki Tsujii, Taku Tashiro, Ichizo Kobayashi, Takahiro Inoue, Atsushi Yonezawa, Shinichiro Shinzaki, Naoto Osugi, Yuko Sakakibara, Yuriko Otake, Tetsuhisa Kitamura, Satoshi Hiyama, Tetsuo Takehara, Takuya Yamada, Takashi Kizu, Yoshito Hayashi, Akiko Asakura, Hideharu Ogiyama, Masato Komori, Koji Nagaike, Takeo Yoshihara, Toshio Yamaguchi, Yuri Tsujii, Hideki Iijima, Ryotaro Uema, Mizuki Tani, Satoshi Egawa, Yuki Arimoto, Takahiro Amano, Minoru Katō, Yoko Murayama, Shoichiro Kawai
article en
5 citations

Abstract

Serum leucine-rich alpha-2 glycoprotein (LRG) can monitor disease activities during biologics treatment in patients with inflammatory bowel disease (IBD). It is unclear whether the pretreatment serum LRG level can predict clinical effectiveness including serum trough levels of ustekinumab in patients with IBD. This multicenter prospective cohort study included 184 patients (Crohn's disease, 104; ulcerative colitis, 80) who received ustekinumab (n = 119) or anti-tumor necrosis factor (n = 65) between January 2019 and March 2023. Multivariate logistic regression analysis revealed serum LRG level at week 0 (0w-LRG, odds ratio 0.12, 95% confidence interval 0.02-0.68) as one of significant factors for clinical remission at week 8. We divided patients into the low- and the high-LRG groups by the median 0w-LRG (18.2 µg/mL) and compared the effectiveness. In patients who received ustekinumab, the proportion of clinical remission at week 8 was significantly different between in the low- (76.9%) and in the high-LRG group (59.3%, P = 0.038), and median serum trough level at week 8 was significantly different between in the low- (10.9 µg/mL, interquartile range 6.7-13.4) and the high-LRG group (5.3 µg/mL, interquartile range 2.4-8.3, P < 0.001). The 0w-LRG can predict the effectiveness including serum trough levels of ustekinumab during induction treatment for patients with IBD.

Scientific ReportsVol. 14(1)
Keio University (JP), Osaka Prefectural Medical Center (JP), Toyonaka Municipal Hospital (JP), Osaka National Hospital (JP), Osaka City General Hospital (JP), Ikeda Municipal Hospital (JP), Osaka Police Hospital (JP), Osaka Rosai Hospital (JP), Kansai Rosai Hospital (JP), Suita Municipal Hospital (JP), Osaka Hospital (JP), Itami City Hospital (JP), Japan Community Healthcare Organization (JP), Kyoto University Hospital (JP), Hyogo Prefectural Nishinomiya Hospital (JP), Osaka University Hospital (JP), Otemae Hospital (JP), Hyogo University (JP), The University of Osaka (JP)
Keio University, Nara Medical University, Japan Society for the Promotion of Science
Good health and well-being
Openalex Percentile: Top 15%
Clusterin in disease pathology
1.41
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.